Recruiting

Testing a medication to help people starting kidney dialysis

Plain-English translation of NCT05786443 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called empagliflozin to see if it can help protect kidney function and improve health in people who are starting hemodialysis due to end-stage kidney disease. Half of the participants will receive the medication daily, and the other half will receive a placebo (a pill with no active ingredient). The study will last 12 weeks and will track how safe the medication is and whether it helps prevent complications.

People on hemodialysis often lose what little remaining kidney function they have left, which can lead to serious health problems. Researchers want to see if this medication might help preserve that remaining function and improve outcomes for dialysis patients.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with end-stage kidney disease and are currently on hemodialysis three times per week
you still have some remaining kidney function (you produce at least 200 mL of urine per day)
you are able to understand the study and give informed consent to participate
if you are a woman who can become pregnant, you have a negative pregnancy test at screening

You likely don't qualify if…

you produce less than 200 mL of urine per day
you are planning to have a kidney transplant within the next 3 months
you have had multiple urinary tract infections or are taking antibiotics to prevent them
you have severe heart failure or have had a recent heart attack, stroke, or heart surgery in the past 12 weeks
you are currently taking another SGLT2 inhibitor medication (a similar drug class)

What participation looks like

If you join this study, you will take either the medication or a placebo pill once daily for 12 weeks while continuing your regular hemodialysis schedule. You will visit the research center for check-ups and blood tests to see how the medication is working and to monitor your health and kidney function. The study team will carefully track any side effects and how you are doing throughout the 12-week period.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(2 sites)

United States

Brigham and Women's Hospital, Boston, Massachusetts

NYU Langone Health, New York, New York